These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 31749795)

  • 1. The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma.
    Zhang Y; Lin Z; Wan Y; Cai H; Deng L; Li R
    Front Immunol; 2019; 10():2472. PubMed ID: 31749795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
    Lam H; McNeil LK; Starobinets H; DeVault VL; Cohen RB; Twardowski P; Johnson ML; Gillison ML; Stein MN; Vaishampayan UN; DeCillis AP; Foti JJ; Vemulapalli V; Tjon E; Ferber K; DeOliveira DB; Broom W; Agnihotri P; Jaffee EM; Wong KK; Drake CG; Carroll PM; Davis TA; Flechtner JB
    Cancer Discov; 2021 Mar; 11(3):696-713. PubMed ID: 33504579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
    Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
    Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.
    Bekri S; Rodney-Sandy R; Gruenstein D; Mei A; Bogen B; Castle J; Levey D; Cho HJ
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.
    Xu A; Zhang L; Chen Y; Lin Z; Li R
    Cancer Immunol Immunother; 2017 Feb; 66(2):181-192. PubMed ID: 27872951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
    PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex.
    Kim SH; Lee BR; Kim SM; Kim S; Kim MS; Kim J; Lee I; Kim HS; Nam GH; Kim IS; Song K; Choi Y; Lee DS; Park WY
    Exp Mol Med; 2024 Jun; 56(6):1461-1471. PubMed ID: 38866910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
    Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
    Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.
    Maciag PC; Seavey MM; Pan ZK; Ferrone S; Paterson Y
    Cancer Res; 2008 Oct; 68(19):8066-75. PubMed ID: 18829565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity.
    Fan T; Xu C; Wu J; Cai Y; Cao W; Shen H; Zhang M; Zhu H; Yang J; Zhu Z; Ma X; Ren J; Huang L; Li Q; Tang Y; Yu B; Chen C; Xu M; Wang Q; Xu Z; Chen F; Liang S; Zhong Z; Jamroze A; Tang DG; Li H; Dong C
    Sci Adv; 2024 Oct; 10(41):eadn9961. PubMed ID: 39392882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
    Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
    J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines.
    Chen T; Hu R; Wan Y; Sun F; Wang Z; Yue J; Chen J; Han G; Wei G; Dong Z
    Biochem Biophys Res Commun; 2020 May; 525(3):607-613. PubMed ID: 32115148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site.
    Lopes A; Feola S; Ligot S; Fusciello M; Vandermeulen G; Préat V; Cerullo V
    J Immunother Cancer; 2019 Jul; 7(1):174. PubMed ID: 31291991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
    Mørk SK; Skadborg SK; Albieri B; Draghi A; Bol K; Kadivar M; Westergaard MCW; Stoltenborg Granhøj J; Borch A; Petersen NV; Thuesen N; Rasmussen IS; Andreasen LV; Dohn RB; Yde CW; Noergaard N; Lorentzen T; Soerensen AB; Kleine-Kohlbrecher D; Jespersen A; Christensen D; Kringelum J; Donia M; Hadrup SR; Marie Svane I
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.